Benta Pharma Industries Announces 2024 First Quarterly Financial Results: Accelerating the Commercialization of Innovative Products and Continuing to Promote Innovation Transformation

In the first quarter of 2024, Benta Pharma Industries obtained market approval for multiple innovative products, benefiting more patients in China. Among them, the rabies vaccine (Vero cell) for human use (freeze-dried), which is independently developed by the Group, has been approved for launch in Chinese mainland. The vaccine is in freeze-dried injectable form and the gene sequence of the CTN-1V strain used in its production is closer to the currently prevalent street strains of the rabies virus, demonstrating good safety and better immune protection effect. Fosun Pharma’s independently developed F-i6000 fully automated chemiluminescence immunoassay analyzer also received approval for launch. The F-i6000 is a high-speed immunoassay analyzer for which the Group has complete intellectual property rights. It can be integrated into laboratory automation systems, providing comprehensive solutions.